<DOC>
	<DOCNO>NCT02458092</DOCNO>
	<brief_summary>The purpose study determine whether investigational malaria vaccine safe induces immune response malaria test adult live United States .</brief_summary>
	<brief_title>Controlled Double Blind Study Evaluate Safety , Reactogenicity , Immunogenicity Candidate Plasmodium Falciparum Malaria Protein 010 ( FMP010 ) Administered Intramuscularly With GSK Biologicals ' Adjuvant AS01B</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>• A male nonlactating female 18 50 year age ( inclusive ) time screen Free significant health problem establish medical history clinical examination enter study Available participate duration study ( approximately seven month ) If subject female , must nonchildbearing potential ( either surgically sterilize one year postmenopausal ) , childbearing potential , must negative pregnancy test time vaccination , capable prevent pregnancy least one month prior determination eligibility ( include abstinence contraceptive ( example intrauterine contraceptive device ; oral contraceptive ; Norplant® DepoProvera® ) , must agree continue precaution two month completion vaccination series . Written informed consent must obtain subject screening procedure . • Prior receipt investigational malaria vaccine Prior receipt vaccine contain either QS21 , MPL AS02A AS01B Use investigational nonregistered drug vaccine study vaccine within 30 day precede first dose study vaccine , plan use study period Administration chronic ( defined 14 day ) immunosuppressant immune modify drug within six month vaccination . For corticosteroid , define prednisone , equivalent , 0.5 mg/kg/day . Inhaled topical steroid allow . Planned administration vaccine foreseen study protocol within 30 day first dose study vaccine . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection A family history congenital hereditary immunodeficiency Chronic active neurologic disease include seizure disorder History splenectomy Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination abnormal baseline laboratory screen test ALT normal range Creatinine normal range Hemoglobin normal range Platelet count normal range Total white cell count normal Acute disease time enrollment ( acute disease define presence moderate severe illness without fever ) . All vaccine administer person minor illness , diarrhea mild upper respiratory infection without fever , i.e . Oral temperature &lt; 37.5°C . Hepatomegaly , right upper quadrant abdominal pain tenderness Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period Pregnant lactate female Suspected know current alcohol abuse/drug abuse obtain history physical examination Female willing intend become pregnant study Any history allergic reaction anaphylaxis previous vaccination Unwilling allow blood sample store future use Inability make follow visit Allergy kanamycin , nickel , imidazole Any significant finding opinion investigator would increase risk adverse outcome participate study Previous allergy Rabies Vaccine Allergy chicken chicken product</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>